Abstrakt:
Until a few years ago, the mainstay of anti-platelet
therapy in patients with acute coronary syndrome
(ACS) was the combination of aspirin and clopidogrel,
a P2Y12 receptor inhibitor. However, current
clinical practice has now changed with the introduction
of ticagrelor, a more potent cardiovascular
drug than clopidogrel, without the limitations
related to clopidogrel therapy. In this review, we
provide a critical overview of ticagrelor in ACS,
highlight the results with ticagrelor in several subgroups
of patients and discuss the future trials.
